Follow The Filings

TNYA Tenaya Therapeutics

Tenaya Therapeutics earnings company data as of 4:48 AM ET 10/23

Limited consensus data for this ticker (thin coverage or data-plan limits). Dates may be company-announced rather than sell-side consensus. Calendar and recent prints remain the primary lens when available.

Scheduled

1 period, newest first, nothing reported yet. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 9 Nov EPS — — —
Rev — — —

Insider trades

Open-market buys and sales by TNYA's executives, directors and 10% owners in the last 12 months, from their Form 4s

All TNYA insider trades
  • None no insider bought on the open market
  • $5.9M sold by 1 insider outside a trading plan
  • None no planned (10b5-1) sales
  1. Column Group Iii Gp, LP 10% owner, +7 joint filers
    Sale
    $2.4M 4,170,266 shares at $0.5700 100% of stake
    Traded Feb 24–25 Filed Feb 26
    ↗
  2. Column Group Iii Gp, LP 10% owner, +7 joint filers
    Sale
    $505K 829,734 shares at $0.6100 27% of stake
    Traded Feb 20–23 Filed Feb 24
    ↗
  3. Column Group Iii Gp, LP 10% owner, +7 joint filers
    Sale
    $3M 4,400,290 shares at $0.6900 62% of stake
    Traded Feb 10–11 Filed Feb 12
    ↗

Also filed in the last 12 months, not counted as buying or selling: 23 sales to cover taxes and 5 stock grants.

SEC filings

Recent issuer filings from EDGAR, 17 shown.

Filed Form Detail Links
DEF 14A Filing Doc
DEFA14A Filing Doc
SCHEDULE 13G — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
8-K 1.02 Filing Doc
8-K 5.02,7.01,9.01 Filing Doc
8-K 5.02,5.07,9.01 Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
8-K 2.02,9.01 Filing Doc
10-K Filing Doc
8-K 1.01 Filing Doc
SCHEDULE 13D/A — Filing Doc
SCHEDULE 13D/A — Filing Doc

Source: SEC EDGAR submissions, updated about 5 hours ago. All on EDGAR

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.